Which is better, GMAB or INCY?

On the Buffett-Fit framework, Incyte Corporation (INCY) currently grades higher than GMAB — 63/100 (C grade) vs 65/100 (C). That said, "better" depends on which framework you trust — GMAB wins on Warren Buffett, Joel Greenblatt, Charlie Munger, and Terry Smith; INCY wins on Benjamin Graham, Philip Fisher, and Peter Lynch. The full pillar breakdown is on this page.

Should I buy GMAB or INCY?

This page is an educational comparison, not investment advice. Both GMAB and INCY are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GMAB better than INCY for value investing?

The two are close on the headline Buffett-Fit score (65/100 vs 63/100), so "better for value investing" depends on which pillar you weight most. The five Buffett pillars + six other frameworks are broken down side-by-side on this page so you can pick the one that fits your style.

What's the difference between GMAB and INCY on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GMAB currently scores 65/100 (C grade); INCY scores 63/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GMAB or INCY?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GMAB and INCY are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GMAB or INCY?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GMAB and INCY both Healthcare stocks?

Yes — both Genmab A/S (GMAB) and Incyte Corporation (INCY) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GMAB vs INCY comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Genmab A/S

Incyte

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

INCY

Incyte

Market cap

$19.41B

Sector

Healthcare

Overall winner

Incyte INCY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	GMAB	INCY	Winner
Warren Buffett	65C	63C	GMAB
Benjamin Graham	64C	73B	INCY
Philip Fisher	48D	61C	INCY
Peter Lynch	25F	50C	INCY
Joel Greenblatt	76B	45D	GMAB
Charlie Munger	68C	60C	GMAB
Terry Smith	71C	66B	GMAB

Side-by-side metrics

Metric	GMAB	INCY
Market cap	$16.5B	$19.41B
P/E (TTM)	6.2x	14.0x
EV/EBIT	12.0x	12.4x
ROIC (TTM)	43.78%	19.98%
Gross margin	93.88%	91.86%
Net margin	18.23%	26.71%
Revenue CAGR 5y	-18.45%	14.55%
EPS CAGR 5y	-23.48%	11.26%
Debt / Equity	0.1x	0.0x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMAB leads on

P/E (TTM)6.2xvs 14.0x+56%
ROIC (TTM)43.78%vs 19.98%+54%

INCY leads on

Revenue CAGR 5y14.55%vs -18.45%+179%
EPS CAGR 5y11.26%vs -23.48%+148%
Debt / Equity0.0xvs 0.1x+92%
Net margin26.71%vs 18.23%+32%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Genmab A/S

Incyte

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like GMAB

More like INCY

Related on invest-like

Key terms in this analysis